A new central direct dopaminergic stimulant: 1-(Coumaran-5-yl methyl)-4-(2-thiazolyl) piperazine hydrochloride (S 3608).
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001572:Benzofurans / Q000494:pharmacology*; D002389:Catatonia / Q000139:chemically induced; D003342:Corpus Striatum / Q000502:physiology; D004347:Drug Interactions; D004873:Ergolines / Q000494:pharmacology; D006801:Humans; D006892:Hydroxydopamines; D008297:Male; D009020:Morphine / Q000494:pharmacology; D010879:Piperazines; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D013378:Substantia Nigra / Q000502:physiology; D013844:Thiazoles / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D001572:Benzofurans; D004873:Ergolines; D006892:Hydroxydopamines; D010879:Piperazines; D013844:Thiazoles; D015016:Yohimbine; C011601:1-(coumaran-5-ylmethyl)-4-(2-thiazolyl)piperazine; D009020:Morphine; D001058:Apomorphine